|
1
|
Caglevic C, Anabalón J, Soza C, Milla E,
Gaete F, Carrasco AM, Panay S, Gallardo C and Mahave M:
Triple-negative breast cancer: The reality in Chile and in Latin
America. Ecancermedicalscience. 13:8932019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Metzger-Filho O, Tutt A, de Azambuja E,
Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis
P, et al: Dissecting the heterogeneity of triple-negative breast
cancer. J Clin Oncol. 30:1879–1887. 2012. View Article : Google Scholar
|
|
3
|
Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH,
Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, et al: Biomarker
assessment of the CBCSG006 trial: A randomized phase III trial of
cisplatin plus gemcitabine compared with paclitaxel plus
gemcitabine as first-line therapy for patients with metastatic
triple-negative breast cancer. Ann Oncol. 29:1741–1747. 2018.
View Article : Google Scholar
|
|
4
|
Leon-Ferre RA, Polley MY, Liu H, Gilbert
JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J,
Thomas A, et al: Impact of histopathology, tumor-infiltrating
lymphocytes, and adjuvant chemotherapy on prognosis of
triple-negative breast cancer. Breast Cancer Res Treat. 167:89–99.
2018. View Article : Google Scholar
|
|
5
|
Chen H, Wu J, Zhang Z, Tang Y and Li X,
Liu S, Cao S and Li X: Association between BRCA status and
triple-negative breast cancer: A meta-analysis. Front Pharmacol.
9:9092018. View Article : Google Scholar
|
|
6
|
Lee JS, Yost SE and Yuan Y: Neoadjuvant
treatment for triple negative breast cancer: Recent progresses and
challenges. Cancers (Basel). 12:14042020. View Article : Google Scholar
|
|
7
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar
|
|
8
|
Baselga J, Gómez P, Greil R, Braga S,
Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, et
al: Randomized phase II study of the anti-epidermal growth factor
receptor monoclonal antibody cetuximab with cisplatin versus
cisplatin alone in patients with metastatic triple-negative breast
cancer. J Clin Oncol. 31:2586–2592. 2013. View Article : Google Scholar
|
|
9
|
Abramson VG, Lehmann BD, Ballinger TJ and
Pietenpol JA: Subtyping of triple-negative breast cancer:
Implications for therapy. Cancer. 121:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar
|
|
11
|
Burstein MD, Tsimelzon A, Poage GM,
Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK,
Hilsenbeck SG, Chang JC, et al: Comprehensive genomic analysis
identifies novel subtypes and targets of triple-negative breast
cancer. Clin Cancer Res. 21:1688–1698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu YR, Jiang YZ, Xu XE, Yu KD, Jin X, Hu
X, Zuo WJ, Hao S, Wu J, Liu GY, et al: Comprehensive transcriptome
analysis identifies novel molecular subtypes and subtype-specific
RNAs of triple-negative breast cancer. Breast Cancer Res.
18:332016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cserni G, hmielik E, Cserni B and Tot T:
The new TNM-based staging of breast cancer. Virchows Arch.
472:697–703. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Amirikia KC, Mills P, Bush J and Newman
LA: Higher population-based incidence rates of triple-negative
breast cancer among young African-American women: Implications for
breast cancer screening recommendations. Cancer. 117:2747–2753.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Becker S: A historic and scientific review
of breast cancer: The next global healthcare challenge. Int J
Gynaecol Obstet. 131 (Suppl 1):S36–S39. 2015. View Article : Google Scholar
|
|
16
|
Thompson AM and Moulder-Thompson SL:
Neoadjuvant treatment of breast cancer. Ann Oncol. 23 (Suppl
10):x231–x236. 2012. View Article : Google Scholar
|
|
17
|
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES,
Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant
capecitabine for breast cancer after preoperative chemotherapy. N
Engl J Med. 376:2147–2159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balic M, Thomssen C, Würstlein R, Gnant M
and Harbeck N: St. Gallen/Vienna 2019: A brief summary of the
consensus discussion on the optimal primary breast cancer
treatment. Breast Care (Basel). 14:103–110. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cardoso F, Kyriakides S, Ohno S,
Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S and Senkus E;
ESMO Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
Early breast cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up†. Ann Oncol. 30:1194–1220. 2019.
View Article : Google Scholar
|
|
20
|
Burstein HJ, Curigliano G, Loibl S, Dubsky
P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M,
Regan M, et al: Estimating the benefits of therapy for early-stage
breast cancer: The St. Gallen international consensus guidelines
for the primary therapy of early breast cancer 2019. Ann Oncol.
30:1541–155. 2019. View Article : Google Scholar
|
|
21
|
Mamounas EP, Anderson SJ, Dignam JJ, Bear
HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL and Wolmark N:
Predictors of locoregional recurrence after neoadjuvant
chemotherapy: Results from combined analysis of national surgical
adjuvant breast and bowel project B-18 and B-27. J Clin Oncol.
30:3960–3966. 2012. View Article : Google Scholar
|
|
22
|
Goto W, Kashiwagi S, Takada K, Asano Y,
Takahashi K, Fujita H, Takashima T, Tomita S, Hirakawa K and Ohira
M: Significance of intrinsic breast cancer subtypes on the
long-term prognosis after neoadjuvant chemotherapy. J Transl Med.
16:3072018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barron AU, Hoskin TL, Day CN, Hwang ES,
Kuerer HM and Boughey JC: Association of low nodal positivity rate
among patients with ERBB2-positive or triple-negative breast cancer
and breast pathologic complete response to neoadjuvant
chemotherapy. JAMA Surg. 153:1120–1126. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Symmans WF, Wei C, Gould R, Yu X, Zhang Y,
Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, et al: Long-term
prognostic risk after neoadjuvant chemotherapy associated with
residual cancer burden and breast cancer subtype. J Clin Oncol.
35:1049–1060. 2017. View Article : Google Scholar
|
|
25
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar
|
|
26
|
Bachegowda LS, Makower DF and Sparano JA:
Taxanes: Impact on breast cancer therapy. Anticancer Drugs.
25:512–521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Untch M, Jackisch C, Schneeweiss A, Conrad
B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S,
Hilfrich J, et al: Nab-paclitaxel versus solvent-based paclitaxel
in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG
69): A randomised, phase 3 trial. Lancet Oncol. 17:345–356. 2016.
View Article : Google Scholar
|
|
28
|
Gianni L, Mansutti M, Anton A, Calvo L,
Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, et
al: Comparing neoadjuvant nab-paclitaxel vs paclitaxel both
followed by anthracycline regimens in women with
ERBB2/HER2-negative breast cancer-the evaluating treatment with
neoadjuvant abraxane (ETNA) trial: A randomized phase 3 clinical
trial. JAMA Oncol. 4:302–308. 2018. View Article : Google Scholar
|
|
29
|
Sharma P, López-Tarruella S, García-Saenz
JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz
Y, Barnadas A, et al: Efficacy of neoadjuvant carboplatin plus
docetaxel in triple-negative breast cancer: Combined analysis of
two cohorts. Clin Cancer Res. 23:649–657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Atchley DP, Albarracin CT, Lopez A, Valero
V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN and Arun BK: Clinical
and pathologic characteristics of patients with BRCA-positive and
BRCA-negative breast cancer. J Clin Oncol. 26:4282–4288. 2008.
View Article : Google Scholar
|
|
31
|
Mavaddat N, Barrowdale D, Andrulis IL,
Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M,
Sherman M, et al: Pathology of breast and ovarian cancers among
BRCA1 and BRCA2 mutation carriers: Results from the consortium of
investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol
Biomarkers Prev. 21:134–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Greenup R, Buchanan A, Lorizio W, Rhoads
K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P
and Shelley Hwang E: Prevalence of BRCA mutations among women with
triple-negative breast cancer (TNBC) in a genetic counseling
cohort. Ann Surg Oncol. 20:3254–3258. 2013. View Article : Google Scholar
|
|
33
|
Stefansson OA, Villanueva A, Vidal A,
Martí L and Esteller M: BRCA1 epigenetic inactivation predicts
sensitivity to platinum-based chemotherapy in breast and ovarian
cancer. Epigenetics. 7:1225–1229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Byrski T, Gronwald J, Huzarski T,
Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski
R, Siolek M, et al: Pathologic complete response rates in young
women with BRCA1-positive breast cancers after neoadjuvant
chemotherapy. J Clin Oncol. 28:375–379. 2010. View Article : Google Scholar
|
|
35
|
Alba E, Chacon JI, Lluch A, Anton A,
Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N,
et al: A randomized phase II trial of platinum salts in basal-like
breast cancer patients in the neoadjuvant setting. Results from the
GEICAM/2006-03, multicenter study. Breast Cancer Res Treat.
136:487–493. 2012. View Article : Google Scholar
|
|
36
|
von Minckwitz G, Schneeweiss A, Loibl S,
Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S,
Gerber B, et al: Neoadjuvant carboplatin in patients with
triple-negative and HER2-positive early breast cancer (GeparSixto;
GBG 66): A randomised phase 2 trial. Lancet Oncol. 15:747–756.
2014. View Article : Google Scholar
|
|
37
|
Sikov WM, Berry DA, Perou CM, Singh B,
Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER,
et al: Impact of the addition of carboplatin and/or bevacizumab to
neoadjuvant once-per-week paclitaxel followed by dose-dense
doxorubicin and cyclophosphamide on pathologic complete response
rates in stage II to III triple-negative breast cancer: CALGB 40603
(Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar
|
|
38
|
Hahnen E, Lederer B, Hauke J, Loibl S,
Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU,
Jackisch C, et al: Germline mutation status, pathological complete
response, and disease-free survival in triple-negative breast
cancer: Secondary analysis of the GeparSixto randomized clinical
trial. JAMA Oncol. 3:1378–1385. 2017. View Article : Google Scholar
|
|
39
|
Poggio F, Bruzzone M, Ceppi M, Pondé NF,
La Valle G, Del Mastro L, de Azambuja E and Lambertini M:
Platinum-based neoadjuvant chemotherapy in triple-negative breast
cancer: A systematic review and meta-analysis. Ann Oncol.
29:1497–1508. 2018. View Article : Google Scholar
|
|
40
|
Loibl S, O'Shaughnessy J, Untch M, Sikov
WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag
D, et al: Addition of the PARP inhibitor veliparib plus carboplatin
or carboplatin alone to standard neoadjuvant chemotherapy in
triple-negative breast cancer (BrighTNess): A randomised, phase 3
trial. Lancet Oncol. 19:497–509. 2018. View Article : Google Scholar
|
|
41
|
Schneeweiss A, Möbus V, Tesch H, Hanusch
C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, et al:
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus
weekly paclitaxel, liposomal doxorubicin (plus carboplatin in
triple-negative breast cancer) for neoadjuvant treatment of
high-risk early breast cancer (GeparOcto-GBG 84): A randomised
phase III trial. Eur J Cancer. 106:181–192. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li ZY, Zhang Z, Cao XZ, Feng Y and Ren SS:
Platinum-based neoadjuvant chemotherapy for triple-negative breast
cancer: A systematic review and meta-analysis. J Int Med Res.
48:3000605209643402020.PubMed/NCBI
|
|
43
|
Telli ML, McMillan A, Ford J, Richardson
AL, Silver D, Isakoff SJ, Kaklamani VG, Gradishar W, Stearns V,
Connolly RM, et al: Abstract P3-07-12: Homologous recombination
deficiency (HRD) as a predictive biomarker of response to
neoadjuvant platinum-based therapy in patients with triple negative
breast cancer (TNBC): A pooled analysis. Cancer Res. 76 (4
Suppl):P3-07-12. 2016.
|
|
44
|
Loibl S, Weber KE, Timms KM, Elkin EP,
Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun
S, et al: Survival analysis of carboplatin added to an
anthracycline/taxane-based neoadjuvant chemotherapy and HRD score
as predictor of response-final results from GeparSixto. Ann Oncol.
29:2341–2347. 2018. View Article : Google Scholar
|
|
45
|
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X,
Xiao Y, Yu KD, Liu YR, Yu Y, et al: Genomic and transcriptomic
landscape of triple-negative breast cancers: Subtypes and treatment
strategies. Cancer Cell. 35:428–440.e5. 2019. View Article : Google Scholar
|
|
46
|
Tutt A, Tovey H, Cheang MCU, Kernaghan S,
Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P,
et al: Carboplatin in BRCA1/2-mutated and triple-negative breast
cancer BRCAness subgroups: the TNT Trial. Nat Med. 24:628–637.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pommier Y, O'Connor MJ and de Bono J:
Laying a trap to kill cancer cells: PARP inhibitors and their
mechanisms of action. Sci Transl Med. 8:362ps172016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fasching PA, Link T, Hauke J, Seither F,
Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A,
et al: Neoadjuvant paclitaxel/olaparib in comparison to
paclitaxel/carboplatinum in patients with HER2-negative breast
cancer and homologous recombination deficiency (GeparOLA study).
Ann Oncol. 32:49–57. 2021. View Article : Google Scholar
|
|
49
|
Rugo HS, Olopade OI, DeMichele A, Yau C,
van't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M,
Perlmutter J, et al: Adaptive randomization of
veliparib-carboplatin treatment in breast cancer. N Engl J Med.
375:23–34. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Severson TM, Wolf DM, Yau C, Peeters J,
Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, et
al: The BRCA1ness signature is associated significantly with
response to PARP inhibitor treatment versus control in the I-SPY 2
randomized neoadjuvant setting. Breast Cancer Res. 19:992017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Telli ML, Jensen KC, Vinayak S, Kurian AW,
Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir
IL, et al: Phase II study of gemcitabine, carboplatin, and iniparib
as neoadjuvant therapy for triple-negative and BRCA1/2
mutation-associated breast cancer with assessment of a tumor-based
measure of genomic instability: PrECOG 0105. J Clin Oncol.
33:1895–1901. 2015. View Article : Google Scholar
|
|
52
|
Tarantino P and Curigliano G: Defining the
immunogram of breast cancer: A focus on clinical trials. Expert
Opin Biol Ther. 19:383–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Marra A, Viale G and Curigliano G: Recent
advances in triple negative breast cancer: The immunotherapy era.
BMC Med. 17:902019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schmid P, Salgado R, Park YH,
Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent
R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment
of high-risk, early-stage triple-negative breast cancer: Results
from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann
Oncol. 31:569–581. 2020. View Article : Google Scholar
|
|
55
|
Bergin ART and Loi S: Triple-negative
breast cancer: Recent treatment advances. F1000Res. 8:13422019.
View Article : Google Scholar
|
|
56
|
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai
L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, et al:
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic
complete response in women with early-stage breast cancer: An
analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.
JAMA Oncol. 6:676–684. 2020. View Article : Google Scholar
|
|
57
|
Loibl S, Untch M, Burchardi N, Huober J,
Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C,
et al: A randomised phase II study investigating durvalumab in
addition to an anthracycline taxane-based neoadjuvant therapy in
early triple-negative breast cancer: Clinical results and biomarker
analysis of GeparNuevo study. Ann Oncol. 30:1279–1288. 2019.
View Article : Google Scholar
|
|
58
|
Schmid P, Cortes J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Pembrolizumab for early triple-negative breast cancer. N Engl J
Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gianni L, Huang CS, Egle D, Bermejo B,
Zamagni C, Thill M, Antón A, Zambelli S, Bianchini G, Russo S, et
al: Abstract GS3-04: Pathologic complete response (pCR) to
neoadjuvant treatment with or without atezolizumab in triple
negative, early high-risk and locally advanced breast cancer.
NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res. 80 (Suppl
4):GS3–04. 2020. View Article : Google Scholar
|
|
60
|
Mittendorf EA, Zhang H, Barrios CH, Saji
S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al:
Neoadjuvant atezolizumab in combination with sequential
nab-paclitaxel and anthracycline-based chemotherapy versus placebo
and chemotherapy in patients with early-stage triple-negative
breast cancer (IMpassion031): A randomised, double-blind, phase 3
trial. Lancet. 396:1090–1100. 2020. View Article : Google Scholar
|
|
61
|
Arora S, Velichinskii R, Lesh RW, Ali U,
Kubiak M, Bansal P, Borghaei H, Edelman MJ and Boumber Y: Existing
and emerging biomarkers for immune checkpoint immunotherapy in
solid tumors. Adv Ther. 36:2638–2678. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tsao MS, Kerr KM, Kockx M, Beasley MB,
Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, et
al: PD-L1 immunohistochemistry comparability study in real-life
clinical samples: Results of blueprint phase 2 project. J Thorac
Oncol. 13:1302–1311. 2018. View Article : Google Scholar
|
|
63
|
Thomas R, Al-Khadairi G and Decock J:
Immune checkpoint inhibitors in triple negative breast cancer
treatment: Promising future prospects. Front Oncol. 10:6005732021.
View Article : Google Scholar
|
|
64
|
Campbell M, Yau C, Borowsky A, Vandenberg
S, Wolf D, Rimm D, Nanda R, Liu M, Brown-Swigart L, Hirst G, et al:
Abstract PD6-08: Analysis of immune infiltrates (assessed via
multiplex fluorescence immunohistochemistry) and immune gene
expression signatures as predictors of response to the checkpoint
inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial. Cancer
Res. 78 (Suppl 4):PD6–08. 2018. View Article : Google Scholar
|
|
65
|
Wolf DM, Yau C, Wulfkuhle J, Petricoin E,
Brown-Swigart L, Hirst G, Asare S; I-SPY 2 Consortium, ; Yee D,
DeMichele A, et al: Abstract 2679: Integration of DNA repair
deficiency and immune biomarkers to predict which early-stage
triple negative breast cancer patients are likely to respond to
platinum-containing regimens vs immunotherapy: The neoadjuvant
I-SPY 2 trial. Cancer Res. 79 (Suppl 13):S26792019.
|
|
66
|
Loibl S, Sinn BV, Karn T, Untch M, Treue
D, Sinn HP, Weber KE, Hanusch CA, Fasching PA, Huober J, et al:
Abstract PD2-07: mRNA signatures predict response to durvalumab
therapy in triple negative breast cancer (TNBC)-results of the
translational biomarker programme of the neoadjuvant double-blind
placebo controlled GeparNuevo trial. Cancer Res. 79 (Suppl
4):PD2–07. 2019.
|
|
67
|
Zgura A, Galesa L, Bratila E and Anghel R:
Relationship between tumor infiltrating lymphocytes and progression
in breast cancer. Maedica (Bucur). 13:317–320. 2018.PubMed/NCBI
|
|
68
|
Kurozumi S, Matsumoto H, Kurosumi M, Inoue
K, Fujii T, Horiguchi J, Shirabe K, Oyama T and Kuwano H:
Prognostic significance of tumour-infiltrating lymphocytes for
oestrogen receptor-negative breast cancer without lymph node
metastasis. Oncol Lett. 17:2647–2656. 2019.
|
|
69
|
Loi S, Druba D, Adams S, Pruneri G,
Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria
S, et al: Tumor-infiltrating lymphocytes and prognosis: A pooled
individual patient analysis of early-stage triple-negative breast
cancers. J Clin Oncol. 37:559–569. 2019. View Article : Google Scholar
|
|
70
|
Dieci MV, Radosevic-Robin N, Fineberg S,
van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso
TM, Demaria S, Castaneda C, et al: Update on tumor-infiltrating
lymphocytes (TILs) in breast cancer, including recommendations to
assess TILs in residual disease after neoadjuvant therapy and in
carcinoma in situ: A report of the international immuno-oncology
biomarker working group on breast cancer. Semin Cancer Biol.
52:16–25. 2018. View Article : Google Scholar
|
|
71
|
Dadiani M, Necula D, Kahana-Edwin S, Oren
N, Baram T, Marin I, Morzaev-Sulzbach D, Pavlovski A, Balint-Lahat
N, Anafi L, et al: TNFR2+ TILs are significantly
associated with improved survival in triple-negative breast cancer
patients. Cancer Immunol Immunother. 69:1315–1326. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Voorwerk L, Slagter M, Horlings HM,
Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC,
Warren S, Ong S, et al: Immune induction strategies in metastatic
triple-negative breast cancer to enhance the sensitivity to PD-1
blockade: The TONIC trial. Nat Med. 25:920–928. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar
|
|
74
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar
|
|
75
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018. View Article : Google Scholar
|
|
76
|
Emens LA, Cruz C, Eder JP, Braiteh F,
Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, et
al: Long-term clinical outcomes and biomarker analyses of
atezolizumab therapy for patients with metastatic triple-negative
breast cancer: A phase 1 study. JAMA Oncol. 5:74–82. 2019.
View Article : Google Scholar
|
|
77
|
Hendry S, Salgado R, Gevaert T, Russell
PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV,
Gonzalez-Ericsson PI, et al: Assessing tumor-infiltrating
lymphocytes in solid tumors: A practical review for pathologists
and proposal for a standardized method from the international
immunooncology biomarkers working group: Part 1: Assessing the host
immune response, TILs in invasive breast carcinoma and ductal
carcinoma in situ, metastatic tumor deposits and areas for further
research. Adv Anat Pathol. 24:235–251. 2017. View Article : Google Scholar
|
|
78
|
Kos Z, Roblin E, Kim RS, Michiels S,
Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, et
al: Pitfalls in assessing stromal tumor infiltrating lymphocytes
(sTILs) in breast cancer. NPJ Breast Cancer. 6:172020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
GiovannelliI P, Di Donato M, Auricchio F,
Castoria G and Migliaccio A: Androgens induce invasiveness of
triple negative breast cancer cells through AR/Src/PI3-K complex
assembly. Sci Rep. 9:44902019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Garufi G, Palazzo A, Paris I, Orlandi A,
Cassano A, Tortora G, Scambia G, Bria E and Carbognin L:
Neoadjuvant therapy for triple-negative breast cancer: Potential
predictive biomarkers of activity and efficacy of platinum
chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin
Pharmacother. 21:687–699. 2020. View Article : Google Scholar : PubMed/NCBI
|
